This article is available to subscribers. Subscribe now. Already have an account? Sign in

Review ArticleFree Preview

Recent Advances in the Treatment of Melanoma

List of authors.
  • Brendan D. Curti, M.D.,
  • and Mark B. Faries, M.D.

The incidence of melanoma has increased, but mortality has declined with improved management. Sentinel-node sampling has reduced morbidity associated with staging surgery, and treatment of advanced disease has improved with the use of targeted therapy and checkpoint immunotherapy.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Curti reports receiving data and safety monitoring board fees from Merck and Eisai, grant support, paid to his institution, and advisory board fees from Clinigen, grant support, paid to his institution, from AstraZeneca and BMS, donated supplies from Galectin Therapeutics, travel support from Agonox, advisory board fees and travel support from Replimune, and advisory board fees from Nektar Therapeutics; and Dr. Faries, receiving advisory board fees from Novartis, Pulse Bioscience, Array Bioscience, Bristol-Myers Squibb, Sanofi, Nektar Therapeutics, and Merck. No other potential conflict of interest relevant to this article was reported.

We thank Walter Urba, M.D., Ph.D., for numerous helpful suggestions, and Kathleen Chilton for assistance in the preparation of an earlier version of the manuscript.

Author Affiliations

From the Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR (B.D.C.); and CedarsCSinai Medical Center and the Angeles Clinic and Research Institute, Los Angeles (M.B.F.).

Address reprint requests to Dr. Curti at the Providence Cancer Institute, Providence Portland Medical Center, 4805 NE Glisan St., Suite 2N82, Portland, OR 97213, or at .

Print Subscriber? Activate your online access.